Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -477.87% is 311% below its 3-year average of -116.25%, near the low end of its 3-year range (-477.87%–-30.30%).
As of the fiscal period ended Tuesday, June 30, 2026. 78.68% below its 12-month average of -267.45%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -477.87%.
RETURN ON EQUITY (ROE)
-477.87%
RETURN ON EQUITY (ROE) AVG TTM
-267.45%
RETURN ON EQUITY (ROE) AVG 3Y
-123.75%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-78.68%
CURRENT VS 3Y AVG
-286.17%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.76%
median of 687 covered companies
CURRENT VS SECTOR MEDIAN
-1072.41%
vs the sector median at left
Neumora Therapeutics, Inc. Common Stock
Market Cap
$89.68M
Return on Equity (ROE)
-477.87%
TTM Avg
-267.45%
3Y Avg
-123.75%
5Y Avg
N/A
Market Cap
$90.32M
Return on Equity (ROE)
48.20%
TTM Avg
-54.60%
3Y Avg
-54.70%
5Y Avg
-44.17%
Market Cap
$89.34M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
Market Cap
$89.60M
Return on Equity (ROE)
-105.20%
TTM Avg
-53.79%
3Y Avg
-41.98%
5Y Avg
-32.71%
Market Cap
$90.25M
Return on Equity (ROE)
N/A
TTM Avg
329.82%
3Y Avg
69.21%
5Y Avg
21.28%
Market Cap
$90.96M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
Market Cap
$91.23M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$87.20M
Return on Equity (ROE)
N/A
TTM Avg
1.45%
3Y Avg
25.22%
5Y Avg
-14.52%
Market Cap
$86.90M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. Common Stock (NMRA) | $89.68M | -477.87% | -267.45% | -123.75% | N/A |
| Rallybio Corporation (RLYB)vs › | $90.32M | 48.20% | -54.60% | -54.70% | -44.17% |
| ImmuCell Corporation (ICCC)vs › | $89.34M | 2.51% | -5.84% | -10.75% | -7.81% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.60M | -105.20% | -53.79% | -41.98% | -32.71% |
| electroCore, Inc. (ECOR)vs › | $90.25M | N/A | 329.82% | 69.21% | 21.28% |
| Equillium, Inc. (EQ)vs › | $90.96M | -32.15% | -60.32% | -93.79% | -79.41% |
| Biomea Fusion, Inc. (BMEA)vs › | $91.23M | -268.09% | -238.76% | -155.55% | -124.74% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.20M | N/A | 1.45% | 25.22% | -14.52% |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 45.93% | 16.96% | -19.36% | -13.87% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.48M | -11.85% | -51.56% | -105.39% | -105.39% |
ROE
-477.9%
ROA
-169.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -477.87% |
| 2026-03-31 | -314.65% |
| 2025-12-31 | -228.10% |
| 2025-09-30 | -178.79% |
| 2025-06-30 | -137.84% |
| 2025-03-31 | -113.00% |
| 2024-12-31 | -84.92% |
| 2024-09-30 | -91.57% |
| 2024-06-30 | -71.91% |
| 2024-03-31 | -59.83% |
| 2023-12-31 | -50.30% |
| 2023-09-30 | -30.30% |
| 2023-03-31 | -33.76% |
